Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 320

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery

Open access
Chang, Joe Y, Mehran, Reza J, Feng, Lei, Verma, Vivek, Liao, Zhongxing, Welsh, James W, Lin, Steven H, O'Reilly, Michael S, Jeter, Melenda D, Balter, Peter A, McRae, Stephen E, Berry, Donald, Heymach, John V, Roth, Jack A, Antonoff, Mara, Hofstetter, Wayne, Rajaram, Ravi, Rice, David, Sepesi, Boris, Swisher, Stephen, Vaporciyan, Ara, Walsh, Garrett, DeGraaf, Craig, Correa, Arlene, Chen, Aileen, Gandhi, Saumil, Komaki, Ritsuko, Lee, Percy, Nguyen, Quynh-Nhu, Ning, Matthew, Gao, Song, Pollard-Larkin, Julianne, Nitsch, Paige, Sadagopan, Ramaswamy, Wang, Xiaochun·2021·The Lancet Oncology

Abstract

Summary Background: A previous pooled analysis of the STARS/ROSEL trials showed higher survival after stereotactic ablative radiotherapy (SABR) compared to surgery for operable early-stage non-small cell lung cancer (NSCLC), but that analysis had notable limitations. This study reports long-term results of the STARS trial, in which the SABR arm was re-accrued with greater sample size, along with a protocol-specified propensity matched comparison with a prospectively registered, contemporary institutional cohort of patients who underwent video-assisted thoracoscopic surgical lobectomy with mediastinal lymph node dissection (VATS L-MLND). Methods: Patients were ≥18 years of age and Zubrod performance status of 0–2, with newly-diagnosed and histologically confirmed ≤3 cm NSCLC with N0M0 disease (squamous cell, adenocarcinoma, large cell, or NSCLC not otherwise specified). This trial (NCT02357992) completed enrollment and did not include patients from the prior pooled analysis. Operability was defined as candidacy for lobectomy as determined by a thoracic surgeon using several objective criteria. PET/CT was required, and EBUS was strongly recommended for all patients. SABR dosing was 54 Gy in three fractions (for peripheral lesions) or 50 Gy in four fractions (for central tumors; simultaneous integrated boost to gross tumor totaling 60 Gy). The primary endpoint was the 3-year overall survival (OS) rate. Non-inferiority could be claimed if the 3-year OS rate after SABR was lower than that after VATS L-MLND by ≤12% and the upper bound of the 95% confidence interval (CI) of the hazard ratio (HR) was <1.965. Propensity matching consisted of determining a propensity score using a multivariable logistic regression model encompassing several covariates (age, tumor size, histology, performance status, and the interaction of age and sex); based on the propensity scores, one SABR patient was randomly matched with one VATS L-MLND patient using a 5-to-1 digit greedy match algorithm. Findings: Enrollment was from September 1, 2015 and completed on January 31, 2017. The median follow-up time for the 80 SABR patients was 5.1 years (IQR, 3.9 – 5.8 years). SABR was tolerated well, with no grade 4–5 toxicity and one case (1.3%) of grade 3 dyspnea. The OS was 91% (95% CI, 85–98%) at 3 years and 87% (95% CI, 79–95%) at 5 years. The OS in the propensity-matched VATS L-MLND cohort was 91% (95% CI 85%–98%) at 3 years and 84% (95% CI 76%–93%) at 5 years. There were no significant OS differences between groups (HR 0.86, 95%CI 0.45–1.65, p=0.65). Interpretation: Long-term survival after SABR is non-inferior to VATS L-MLND for operable stage IA NSCLC. SABR remains promising for such cases but multidisciplinary management is strongly recommended.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(21)00401-0

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 320

Metadata

Authors
Chang, J. Y., Mehran, R. J., Feng, L., Verma, V., Liao, Z., Welsh, J. W., Lin, S. H., O'Reilly, M. S., Jeter, M. D., Balter, P. A., McRae, S. E., Berry, D., Heymach, J. V., Roth, J. A., Antonoff, M., Hofstetter, W., Rajaram, R., Rice, D., Sepesi, B., Swisher, S., Vaporciyan, A., Walsh, G., DeGraaf, C., Correa, A., Chen, A., Gandhi, S., Komaki, R., Lee, P., Nguyen, Q.-N., Ning, M., Gao, S., Pollard-Larkin, J., Nitsch, P., Sadagopan, R., & Wang, X.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2021-10
Volume
22
Issue
10
Pages
1448-1457
ISSN
1470-2045 (ISSN-L)
OpenAlex
W3199515001
Cited by
320
References
20
FWCI
33.19
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. https://app.cochat.ai/papers/10.1016/s1470-2045(21)00401-0
The paper
Chang, J. Y., Mehran, R. J., Feng, L., Verma, V., Liao, Z., Welsh, J. W., Lin, S. H., O'Reilly, M. S., Jeter, M. D., Balter, P. A., McRae, S. E., Berry, D., Heymach, J. V., Roth, J. A., Antonoff, M., Hofstetter, W., Rajaram, R., Rice, D., Sepesi, B., . . . Wang, X. (2021). Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(21)00401-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.